Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll New therapeutic options in the management of COPD - focus on roflumilast Antoniu SAInt J Chron Obstruct Pulmon Dis 2011[]; 6 (ä): 147-55In chronic obstructive pulmonary disease (COPD) the inflammation occurring in the airways and in other lung tissues is complex and is orchestrated by various mediators including the isoenzyme 4 of the phosphodiesterases family (PDE4), which contributes to bronchoconstriction and inflammation. Various PDE4 inhibitors have been evaluated as potential therapies in asthma or COPD but among these only roflumilast have been authorized in Europe to be used in patients with severe COPD as an add-on to the bronchodilator therapy. This review discusses the existing preclinical and clinical data supporting the use of roflumilast for this therapeutic indication and tackles some of the pending issues related to PDE4 in general and to roflumilast in particular.|Aminopyridines/adverse effects/*therapeutic use[MESH]|Animals[MESH]|Anti-Inflammatory Agents/adverse effects/*therapeutic use[MESH]|Benzamides/adverse effects/*therapeutic use[MESH]|Bronchodilator Agents/adverse effects/*therapeutic use[MESH]|Cyclopropanes/adverse effects/therapeutic use[MESH]|Drug Therapy, Combination[MESH]|Humans[MESH]|Lung/*drug effects/physiopathology[MESH]|Phosphodiesterase 4 Inhibitors/adverse effects/*therapeutic use[MESH]|Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology[MESH]|Risk Assessment[MESH]|Treatment Outcome[MESH] |